ND021 is a next-generation multi-specific immuno-oncology program targeting the tumor-immunity suppressive PD(L)-1 pathway and the tumor-immunity activating 4-1BB/CD137 pathway in a single therapeutic molecule. Targeting these two clinically validated pathways in a combinatorial approach is expected to provide patients suffering from a broad range of cancer types with a unique novel treatment opportunity characterized by an improved benefit-to-risk profile as compared to current standard of care as well as other combinatorial immunotherapy approaches currently in clinical development. The differentiating profile of ND021 is based on its molecular design as a monovalent trispecific antibody fragment aimed at highly effective, while only local activation of a tumor-directed specific immune response. Numab develops this product together with its Chinese partner CStone Pharmaceuticals.

Download poster presentation at AACR Annual Meeting 2020